wild-20 and Inflammatory-Bowel-Diseases

A new, orally active de-N-acetylated lysoglycosphingolipid (WILD20) was evaluated as antiinflammatory agent using a model of chemically-induced inflammatory bowel disease (IBD) in the rat to mimic human ulcerative colitis and Chron's disease. IBD was induced by hapten trinitrobenzenesulphonic acid (TNB). WILD20, orally administered as preventive or curative, was demonstrated to be efficacious at daily dosages of 0.1-1 mg/kg for 4-5 days. Damage scores, body weight, spleen weight, colonic tissular levels of LTB4, myeloperoxidase (MPO) and malondialdehyde (MDA) are influenced and brought into parameters of normality. Histological observation demonstrated quicker healing, better repair, reduced inflammation, and poor eosinophil degranulation. The mechanisms underlying WILD20 antiinflammatory effects were investigated: whereas WILD20 fails to show a direct effect on PKC, it reduces PKC translocation to the membrane; cellular PLA2 was consequently greatly reduced through this mechanism and thought to be responsible for WILD20 efficacy towards chemically-induced IBD.

Topics: Animals; Arachidonic Acid; Carbohydrate Sequence; Colitis; Colon; Gangliosides; Humans; Inflammatory Bowel Diseases; Leukotriene B4; Male; Malondialdehyde; Molecular Sequence Data; Organ Size; Pancreas; Peroxidase; Phospholipases A; Phospholipases A2; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Spleen; Synovial Fluid; Trinitrobenzenesulfonic Acid